<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149567">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01771588</url>
  </required_header>
  <id_info>
    <org_study_id>08.08.INF</org_study_id>
    <nct_id>NCT01771588</nct_id>
  </id_info>
  <brief_title>Evaluation of Growth of Pre-Term Infants Fed a Human Milk Fortifier</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It it is hypothesized that the growth of preterm infants receiving a new human milk
      fortifier will be equal or superior to the growth of preterm infants receiving a currently
      marketed human milk fortifier with a lower protein content.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Weight gain (g/d) between full strength fortification with full volume intake (day 1) through 21 days of study after that day.</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Premature Babies</condition>
  <arm_group>
    <arm_group_label>New human milk fortifier</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Currently marketed fortifier</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Human milk fortifier</intervention_name>
    <arm_group_label>New human milk fortifier</arm_group_label>
    <arm_group_label>Currently marketed fortifier</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Birth weight ≤1500 g AND/OR gestational age ≤32 weeks (determined by maternal dates,
             fetal ultrasound, Dubowitz/Ballard examination or a combination thereof)

          -  Male or female

          -  Tolerating an enteral intake of human milk, donor milk or a combination at ≥100
             mL/kg/d for ≥ 24 h

          -  Subject is anticipated to receive human milk, donor milk or a combination for ≥ 3
             consecutive weeks after having achieved full fortification with volume intake
             contained between 150 and 180 mL/kg/d.

          -  Written informed consent has been obtained from the legal representative(s).

        Exclusion Criteria:

          -  Infants with current systemic disease

          -  Infants with a history of systemic disease

          -  Any congenital anomalies of the GI tract that significantly interfere with nutrition
             and growth or previous GI surgery.

          -  Small size for gestational age (SGA) - body weight ≦ 5th percentile for that
             gestational age.

          -  Infants diagnosed with any inherent metabolic disease.

          -  Infants diagnosed with any chromosomic disease.

          -  Receiving any commercial formula supplementation to breast milk.

          -  Receiving steroids at the time of enrollment.

          -  Participation in another nutritional clinical trial that may affect outcomes of this
             study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHR de la Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Rigo</last_name>
      <phone>+32 (4) 225 6322</phone>
      <email>j.rigo@ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jacques Rigo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants - CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude Billeaud</last_name>
      <phone>+33 5 56 79 56 43</phone>
      <email>claude.billeaud@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Claude Billeaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard Guillois, Pr</last_name>
      <phone>+33 (0) 2 .31.27.25.67</phone>
      <email>guillois-b@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard Guillois, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amandine Rubio, Dr</last_name>
      <phone>+33 (0) 4 76 76 87 06</phone>
      <email>arubio@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Amandine Rubio, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Charles Picaud, Pr</last_name>
      <phone>+33 (0) 4 72 00 15 50</phone>
      <email>jean-charles.picaud@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Charles Picaud, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Umberto Simeoni, Pr</last_name>
      <phone>+33 (0) 4 91 38 40 40</phone>
      <email>umberto.simeoni@mail.ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Umberto Simeoni, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maternité Régionale</name>
      <address>
        <city>Nancy</city>
        <zip>54042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel Hascoët</last_name>
      <phone>+33 3 83 34 43 42</phone>
      <email>jm.hascoet@maternite.chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel Hascoët</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Clocheville Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elie Saliba, Pr</last_name>
      <phone>+33 (0) 2 47 47 80 93</phone>
      <email>elie.saliba@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Elie Saliba, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernest von Bergmann</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Radke</last_name>
      <phone>+49 (0) 331 241 59 01</phone>
      <email>mradke@klinikumevb.de</email>
    </contact>
    <investigator>
      <last_name>Michael Radke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Mangiagalli e Regina Elena</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Mosca</last_name>
      <phone>+39 02 550 32 907</phone>
      <email>fabio.mosca@unimi.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Mosca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinderspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Spalinger</last_name>
      <phone>+41 41 205 32 39</phone>
      <email>johannes.spalinger@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Johannes Spalinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
